Individualizing therapy to prevent long-term consequences of estrogen deficiency in postmenopausal women

Archives of Internal Medicine

Volumn 159, Issue 13, 1999, Pages 1458-1466

  Col, Nananda F ^a,d   Pauker, Stephen G ^a   Goldberg, Robert J ^b   Eckman, Mark H ^a   Orr, Richard K ^c   Ross, Elizabeth M ^a   Wong, John B ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c MARSHFIELD CLINIC   (United States)

^d TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ESTROGEN; GESTAGEN; LIPID; RALOXIFENE;

ARTICLE; BONE DENSITY; BREAST CANCER; DRUG EFFECT; DRUG EFFICACY; ESTROGEN DEFICIENCY; FEMALE; HIP FRACTURE; HORMONAL THERAPY; HUMAN; ISCHEMIC HEART DISEASE; LIFE EXPECTANCY; LIPID BLOOD LEVEL; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL;

ALENDRONATE; BONE DENSITY; BREAST NEOPLASMS; CORONARY DISEASE; DECISION SUPPORT TECHNIQUES; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; ESTROGENS, CONJUGATED (USP); FEMALE; HIP FRACTURES; HUMANS; LIFE EXPECTANCY; LIPIDS; MARKOV CHAINS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PIPERIDINES; POSTMENOPAUSE; RALOXIFENE; RISK; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 0033549596     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.159.13.1458     Document Type: Article

References (100)

1. Lindsay R, Bush TL, Grade D, Speroff L, Lobo RA. Therapeutic controversy: estrogen replacement in menopause. J Clin Endocrinol Metab. 1996;81:3829-3838.
2. Paganini-Hill A, Ross RK, Gerkins VR, Henderson BE, Arthur M, Tack TM. Menopausal estrogen therapy and hip fracture. Ann Intern Med. 1981;95:28-31.
3. Harris ST, Genant HK, Baylink DJ, et al. The effects of estrone (Ogen) on spinal bone density of postmenopausal women. Arch Intern Med. 1991;151:1980-1984.
4. Grodstein F, Stampfer MJ, Manson YE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med. 1996;335:453-461.
5. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 1995;332:1589-1593.
6. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol. 1995; 85:304-313.
7. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures: Fracture Intervention Trial Research Group. Lancet. 1996;348:1535-1541.
8. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280:2077-2082.
9. Turner CH, Saro M, Bryant HU. Raloxifene preserves bone strength and bone mass in ovariectomized rats. Endocrinology. 1994;135:2001-2005.
10. Black LJ, Sato M, Rowley ER, et al. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest. 1994;93:63-69.
11. Draper MW, Boss SM, Huster WJ, Neild JA. Effects of raloxifene hydrochloride on serum markers of bone and lipid metabolism - dose-response relationships [abstract]. Calcif Tissue Int. 1994;54:339.
12. Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C. A controlled trial of raloxifene (LY139481) HCI: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res. 1996;11:835-842.
13. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med. 1997;337:1641-1647.
14. Meeting #68 of the Endocrinologic and Metabolic Drugs Advisory Committee, Center for Drug Evaluation and Research, Food and Drug Administration, Public Health Service, Dept of Health and Human Services; November 20, 1997; Bethesda, Md. Transcript available at: http://www.fda.gov/ohrms/dockets/ac/ cder97t.htm.
15. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE Randomized Trial. JAMA. 1999;281:2189-2197.
16. Kiel DP, Felson DT, Anderson JJ, Wilson PW, Moskowitz MA. Hip fracture and the use of estrogens in postmenopausal women: the Framingham Study. N Engl J Med. 1987;317:1169-1174.
17. Aloia JF, Vaswani A, Yeh JK, Ross PL, Flaster E, Dilmanian A. Calcium supplementation with and without hormone replacement therapy to prevent postmenopausal bone loss. Ann Intern Med. 1994;120:97-103.
18. Lindsay R. Hormone replacement therapy for prevention and treatment of osteoporosis. Am J Med. 1993;95(suppl):37S-39S.
19. Lindsay R, Hart DM, Aitken JM, MacDonald EB, Anderson JB, Clarke AC. Long-term prevention of postmenopausal osteoporosis by oestrogen: evidence for an increased bone mass after delayed onset of oestrogen treatment. Lancet. 1976;1:1038-1040.
20. Manson JE. Postmenopausal hormone therapy and atherosclerotic disease. Am Heart J. 1994;128:1337-1343.
21. Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med. 1997;336:1769-1775.
22. Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med. 1991;151:75-78.
23. Hosking D, Chilvers CED, Christiansen C, et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. N Engl J Med. 1998;338:485-492.
24. Ettinger B, Genant HK, Cann CE. Long-term estrogen replacement therapy prevents bone loss and fractures. Ann Intern Med. 1985;102:319-324.
25. Col NF, Eckman MH, Karas RH, et al. Patient-specific decisions about hormone replacement therapy in postmenopausal women. JAMA. 1997;277:1140-1147.
26. Hui SL, Slemenda CW, Johnson CC Jr. Age and bone mass as predictors of fracture in a prospective study. J Clin Invest. 1988;81:1804-1809.
27. Riggs BL, Wahner HW, Seeman E, et al. Changes in bone mineral density on the proximal femur and spine with aging: differences between the postmenopausal and senile osteoporosis syndromes. J Clin Invest. 1982;70:716-723.
28. Mazes RB, Wahner HW. Nuclear medicine and densitometry. In: Riggs BL, Melton LJ, eds. Osteoporosis: Etiology, Diagnosis, and Management. New York, NY: Raven Press; 1988:251-295.
29. Black DM, Cummings SR, Genant HK, Nevitt MC, Palermo L, Browner W. Axial and appendicular bone density predict fractures in older women. J Bone Miner Res. 1992;7:633-638.
30. Libanati CR, Schulz EE, Shook JE, Bock M, Baylink DJ. Hip mineral density in females with a recent hip fracture. J Clin Endocrinol Metab. 1992;74:351-356.
31. Gardsell P, Johnell O, Nilsson BE. The predictive value of bone loss for fragility fractures in women: a longitudinal study over 15 years. Calcif Tissue Int. 1991; 49:90-94.
32. Wasnich RD, Ross PD, Heilbrun LK, Vogel JM. Prediction of postmenopausal fracture risk with use of bone mineral measurements. Am J Obstet Gynecol. 1985;153:745-751.
33. Cummings SR, Black DM, Nevitt MC, et al. Appendicular bone density and age predict hip fracture in women: the Study of Osteoporotic Fractures Research Group. JAMA. 1990;263:665-658.
34. Smith DM, Khairi MRA, Johnston CC Jr. The loss of bone mineral with aging and its relationship to risk of fracture. J Clin Invest. 1975;56:311-318.
35. Tosteson AN, Rosenthal DI, Melton LJ III, Weinstein MC. Cost effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy. Ann Intern Med. 1990;113:594-603.
36. Melton LJ III, Kan SH, Wahner HW, Riggs BL. Lifetime fracture risk: an approach to hip fracture risk assessment based on bone mineral density and age. J Clin Epidemiol. 1988;41:985-994.
37. Cummings SR, Black DM, Nevitt MC, et al. Bone density at various sites for prediction of hip fractures: the Study of Osteoporotic Fractures Research Group. Lancet. 1993;341:72-75.
38. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women: the Study of Osteoporotic Fractures Research Group. N Engl J Med. 1995;332:767-773.
39. Anderson KM, Odell PM, Wilson PWF, Kannel WB. Cardiovascular disease risk profiles. Am Heart J. 1991;121:293-298.
40. Anderson KM, Wilson PWF, Odell PM, Kannel WB. An updated coronary risk profile: a statement for health professionals. Circulation. 1991;83:356-362.
41. Gail MK, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81:1879-1886.
42. Vital Statistics of the United States, 1975: Volume II - Mortality, Part B. Hyattsville, Md: National Center for Health Statistics; 1977. Publication PHS 78-1102.
43. Eaker ED, Chesebro JH, Sacks FM, Wenger NK, Whisnant JP, Winston M. Cardiovascular disease in women. Circulation. 1993;88:1999-2009.
44. McClung M, Clemmesen B, Diafotis A, et al. Alendronate prevents postmenopausal bone loss in women without osteoporosis: a double-blind, randomized, controlled trial: Alendronate Osteoporosis Prevention Study Group. Ann Intern Med. 1998;128:253-261.
45. Evista (raloxifene HCI) [package insert]. Indianapolis, Ind: Eli Lilly & Co; 1997.
46. Lindsay R. Prevention and treatment of osteoporosis. Lancet. 1993;341:801-805.
47. Papapoulos SE. The role of bisphosphonates in the prevention and treatment of osteoporosis. Am J Med. 1993;95(suppl 5A):48S-52S.
48. Guy JA, Shea M, Peter CP, Morrisey R, Hayes WC. Continuous alendronate treatment throughout growth, maturation, and aging in the rat results in increases in bone mass and mechanical properties. Calcif Tissue Int. 1993;53:283-288.
49. Balena R, Toolan BC, Shea M, et al. The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest. 1993;92:2577-2586.
50. Heaney RP, Draper MW. Raloxifene and estrogen: comparative bone remodeling kinetics. J Clin Endocrinol Metab. 1997;82:3425-3429.
51. Gunness M, Preswood K, Lu Y, et al. Histomorphometric, bone marker, and bone mineral density response to raloxifene HCL and premarin in postmenopausal women. In: Program and Abstracts of the 79th Annual Meeting of the Endocrine Society; June 11-14, 1997; Minneapolis, Minn.
52. Steinberg KK, Thacker SB, Smith SJ, et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA. 1991;265: 1985-1990.
53. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117:1016-1037.
54. Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease: 10-year follow-up from the Nurses' Health Study. N Engl J Med. 1991;325:756-762.
55. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet. 1997;350:1047-1059.
56. Hulley S, Grady D, Bush T, et al, for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605-613.
57. Yaffe K, Sawaya G, Lieberburg I, Grady D. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA. 1998;279: 688-695.
58. Yaffe K, Grady D, Pressman A, Cummings S. Serum estrogen levels, cognitive performance, and risk of cognitive decline in older community women. J Am Geriatr Soc. 1998;46:816-821.
59. MacLennan SC, MacLennan AH, Ryan P. Colorectal cancer and oestrogen replacement therapy: a meta-analysis of epidemiological studies. Med J Aust. 1995; 162:491-493.
60. Grodstein F, Martinez E, Platz EA, et al. Postmenopausal hormone use and risk for colorectal cancer and adenoma. Ann Intern Med. 1998;128:705-712.
61. Hoover RN. Cancer prevention: better late than never? Ann Intern Med. 1998; 128:771-772.
62. Daly ED, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet. 1996; 348:977-980.
63. Grady D, Hulley SB, Furberg C. Venous thromboembolic events associated with hormone replacement therapy [letter]. JAMA. 1997;278:477.
64. Douketis ID, Ginsberg JS, Holbrook A, Crowther M, Duku EK, Burrows RF. A reevaluation of the risk for venous thromboembolism with the use of oral contraceptives and hormone replacement therapy. Arch Intern Med. 1997;157: 1522-1530.
65. Grodstein F, Stampfer MJ, Goldhaber SZ, et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet. 1996; 348:983-987.
66. Anderson FA Jr, Wheeler B, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism: the Worcester DVT Study. Arch Intern Med. 1991; 151:933-938.
67. Hillner B, Philbrick JT, Becker DN. Optimal management of suspected lower-extremity deep vein thrombosis: an evaluation with cost assessment of 24 management strategies. Arch Intern Med. 1992;152:165-175.
68. O'Brien BJ, Anderson DR, Goeree R. Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement. CMAJ. 1994;150:1083-1090.
69. Menzin J, Colditz GA, Regan MM, Richner RE, Oster G. Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery. Arch Intern Med. 1995;155:757-764.
70. Colman RW, Rubin RN. Update on pulmonary embolism: modern management. Dis Mon. November 1982;29:1-41.
71. Dalen JE, Alpert JS. Natural history of pulmonary embolism. Prog Cardiovasc Dis. 1975;17:259-270.
72. Gilday DL, Poulose RP, DeLand FH. Accuracy of detection of pulmonary embolism by lung scanning correlated with pulmonary angiography. Am J Roentgenol Radium Ther Nucl Med. 1972;115:732-738.
73. Carson JL, Kelley MA, Duff A, et al. The clinical course of pulmonary embolism. N Engl J Med. 1992;326:1240-1245.
74. National Institutes of Health Consensus Conference. Prevention of venous thrombosis and pulmonary embolism. JAMA. 1986;256:744-749.
75. Kannel WB, Wolf PA, Garrison, RJ. The Framingham Study, Section 35: An Epidemiological Investigation of Cardiovascular Disease: Survival Following Initial Cardiovascular Events: 30-Year Follow-up. Bethesda, Md: National Heart, Lung, and Blood Institute, US Dept of Health and Human Services; 1988. Publication NIH 83-2969.
76. Best PJM, Berger PB, Miller VM, Lerman A. The effect of estrogen replacement therapy on plasma nitric oxide and endothelin-1 levels in postmenopausal women. Ann Intern Med. 1998;128:285-288.
77. Ylikorkata O, Orpana A, Puolakka J, Pyorala T, Dubey RK, Viinikka L. Postmenopausal hormonal replacement decreases plasma levels of endothelin-1. J Clin Endocrinol Metab. 1995;80:3384-3387.
78. Volterrani M, Rosano G, Coats A, Beale C, Collins P. Estrogen acutely increases peripheral blood flow in postmenopausal women. Am J Med. 1995;99: 119-122.
79. Lieberman EH, Gerhard MD, Uehata A, et al. Estrogen improves endothelium-dependert flow-mediated vasodilation in postmenopausal women. Ann Intern Med. 1994;121:936-941.
80. Reis SE, Gloth ST, Blumenthal RS, et al. Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women. Circulation. 1994;89:52-60.
81. Espeland MA, Marcovina SM, Miller V, et al, for the PEPI Investigators. Effect of postmenopausal hormone therapy on lipoprotein(a) concentration. Circulation. 1998;97:979-986.
82. Walsh BW, Kuller LH, Wild RA, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA. 1998;279:1445-1451.
83. Zuckerman SH, Bryan N. Inhibition of LDL oxidation and myeloperoxidase dependent tyrosyl radical formation by the selective estrogen receptor modulator raloxifene (LY139481 HCL). Atherosclerosis. 1996;126:65-75.
84. Rahimian R, Laher I, Dube G, van Breemen C. Estrogen and selective estrogen receptor modulator LY117018 enhance release of nitric oxide in rat aorta. J Pharm Exp Ther. 1997;283:116-122.
85. Bjarnasson NH, Haarbo J, Byrjalsen I, Kauffman RF, Christiansen C. Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized, cholesterol-fed rabbits. Circulation. 1997;96:1964-1969.
86. Wiernicki T, Glasebrook A, Phillips DL, Singh JP. Estrogen and a novel tissue selective estrogen receptor modulator raloxifene directly modulate vascular smooth muscle cell functions: implications in the cardioprotective mechanism of estrogen. Circulation. 1996;94(suppl 1):1-278.
87. Costantino JP, Kuller LH, Ives DG, Fisher B, Dignam J. Coronary heart disease mortality and adjuvant tamoxifen therapy. J Natl Cancer Inst. 1997;89:776-782.
88. McDonald CC, Alexander FE, Whyte BW, Forrest AP, Stewart HJ. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial: the Scottish Cancer Trials Breast Group. BMJ. 1995;311: 977-980.
89. Clarkson TB, Anthony MS, Jerome CP. Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys. J Clin Endocrinol Metab. 1998;83:721-726.
90. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvanat Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371-1388.
91. The Writing Group for the PEPI Trial. Effects of hormone therapy on bone mineral density: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA. 1996;276:1389-1396.
92. Cummings SR, Black DM, Rubin SM. Lifetime risks of hip, Colles', or vertebral fracture and coronary heart disease among white postmenopausal women. Arch Intern Med. 1989;149:2445-2448.
93. de Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med. 1996;335:1016-1021.
94. Black DM, Reiss TF, Nevitt MC, et al. Design of fracture intervention trial. Osteoporos Int. 1993;3(suppl):S29-S39.
95. Colina RE, Smith M, Kikendall JW, Wong RK. A new probable increasing cause of esophageal ulceration: alendronate. Am J Gastroenterol. 1997;92:704-706.
96. Wright JC, Weinstein MC. Gains in life expectancy from medical interventions: standardizing data on outcomes. N Engl J Med. 1998;339:380-386.
97. Lerman C, Kash K, Stefanek M. Younger women at increased risk for breast cancer: perceived risk, psychological well-being, and surveillance behavior. J Natl Cancer Inst Monogr. 1994;16:171-176.
98. Black WC, Nease RF Jr, Tosteson AN. Perceptions of breast cancer risk and screening effectiveness in women younger than 50 years of age. J Natl Cancer Inst. 1995;87:720-731.
99. Pilote L, Hlatky MA. Attitudes of women toward hormone therapy and prevention of heart disease. Am Heart J. 1995;129:1237-1238.
100. Alexander NE, Ross J, Sumner W, Nease RF, Littenberg B. The effect of an educational intervention on the perceived risk of breast cancer. J Gen Intern Med. 1996;11:92-97.